Pond Technologies

LATEST MEDICINAL CANNABIS STOCK NEWS


Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion

Last Trade: 0.03 0.0005 1.79

San Diego, California--(Newsfile Corp. - January 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that its Phase 2 clinical trial protocol has received study level approval from a central institutional review board ("IRB"). The Phase 2 study is a planned evaluation of SBI-100... Read more


IM Cannabis Provides Update to Listed Issuer Financing Exemption Offering

Last Trade: 1.33 0.05 3.91

TORONTO and GLIL YAM, Israel, Jan. 27, 2023 /CNW/ - IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company announces that it has engaged certain eligible finders (each a "Finder"), in connection with its previously announced private placement offering of units of the Company (each, a "Unit") pursuant to the listed issuer financing exemption under Part 5A of... Read more


Body and Mind Announces Q1 2023 Financial Results

Last Trade: 0.06 0.0029 4.68

Reports Quarterly Revenue of US$7.8 Million & Highlights Recent Developments LAS VEGAS and VANCOUVER, BC, Jan. 25, 2023 /CNW/ - Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the "Company" or "BaM"), a multi-state operations-focused cannabis company, is pleased to announce financial results for the first quarter of fiscal year 2023 ended October 31, 2022 and to provide shareholders with an operational... Read more


Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially...

Last Trade: 0.03 0.0005 1.79

Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I clinical study for Skye Bioscience, Inc.’s (SKYE: OTCQB) proprietary, synthetic cannabinoid derivative, SBI-100 Ophthalmic Emulsion (OE), which has been designed to advance a new mechanism of action with potential as a... Read more


Khiron Life Sciences begins dispensation of insurance-covered prescriptions in Colombia

Last Trade: 0.09 0.0077 9.44

Following the Government of Colombia's decision on insurance coverage for medical cannabis, Khiron has begun dispensing medical cannabis to its patient base under the new mandate. TORONTO, Jan. 19, 2023 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces that it has begun dispensing medical cannabis to patients in its wholly owned ZereniaTM... Read more


Body and Mind Announces Fiscal Year End (July) 2022 Financial Results

Last Trade: 0.06 0.0029 4.68

Reports Annual Revenue of US$31.6 Million & Highlights Recent Developments LAS VEGAS and VANCOUVER, BC, Jan. 18, 2023 /CNW/ - Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) (the "Company" or "BaM"), a multi-state operations-focused cannabis company, is pleased to announce financial results for the fiscal year ended July 31, 2022 and to provide shareholders with an operational update. All financial information is... Read more


CV Sciences Launches 30-Count of Popular +PlusCBD™ Reserve Collection Softgels

Last Trade: 0.04 -0.0012 -2.91

Smaller bottle allows for consumers flexibility at a more affordable price SAN DIEGO, Jan. 18, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced the launch of their popular +PlusCBD™ Reserve Collection... Read more


SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

Last Trade: 0.89 -0.03 -3.03

The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders... Read more


Khiron Life Sciences: NHS reimburses the cost of cannabis treatment to the first Zerenia™ Clinics UK patient

Last Trade: 0.09 0.0077 9.44

Zerenia™ Clinics UK, wholly owned by Khiron, succeeds at having the NHS reimbursing both the cost of cannabis-based treatment and clinic fees to its first patient Khiron trains doctors and nurses at an NHS- funded hospital on how to integrate CBMPs (cannabis-based products for medicinal use in humans) to treatment options Khiron will be presenting its new real-world clinical evidence at the upcoming... Read more


Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol...

Last Trade: 0.66 0.03 4.48

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabidiol in FXS, Zygel™ showed a significant reduction in behavioral symptoms,... Read more


Tilray Brands Reports Second Quarter Fiscal Year 2023 Financial Results

Last Trade: 3.21 0.14 4.56

Achieved $29.2 Million of Operating Cash Flow and $25.4 Million of Free Cash Flow 15th Consecutive Quarter of Positive Adjusted EBITDA Maintains Leading Market Share Position in Recreational Cannabis in Canada and Medical Cannabis Across Europe Net Revenue of $144.1 Million, On a Constant Currency Basis $157.6 million EPS of -$0.11 and Adjusted EPS of -$0.06 Strategy in Place to Build the World’s Leading and... Read more


PreveCeutical Medical Signs Intercompany Sol-Gel License Agreement

Last Trade: 0.02 0.0021 9.25

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the... Read more


HEXO Launches Five New Cannabis Strains Under Market-Leading Redecan and Original Stash Brands

Last Trade: 1.59 -0.04 -2.45

New TnT strains expand HEXO's top-selling portfolio and are crafted to create a fulsome sensory experience for the consumer HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the “Company”), a leading producer of high-quality cannabis products, is pleased to announce the launch of its new TnT Cannabis strains under the Redecan and Original Stash Brands labels across Canada. The new strains further expand HEXO’s... Read more


SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center

Last Trade: 0.89 -0.03 -3.03

Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed... Read more


Khiron Life Sciences wins first medical cannabis contract with Colombia's largest public insurance company

Last Trade: 0.09 0.0077 9.44

On December 27, 2022, Zerenia (Khiron´s wholly owned medical cannabis clinic network) signed a contract with CAPITAL SALUD EPS, Colombia´s largest public insurance company, under which Zerenia will provide medical cannabis services and products to its patient population, directly reimbursed by CAPITAL SALUD EPS. CAPITAL SALUD EPS is owned by the City of Bogota and insures more than 1.2 million people in and... Read more


Lexaria Bioscience Receives First Granted Patent in Canada

Last Trade: 2.94 0.10 3.52

KELOWNA, BC / ACCESSWIRE / December 29, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. Canadian Patent #3,093,414 is the first granted patent... Read more


1933 Industries Announces First Quarter 2023 Financial Results and Reports Record Revenue of $5.64 Million

Last Trade: 0.02 -0.0037 -19.47

VANCOUVER, BC / ACCESSWIRE / December 28, 2022 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF) (OTCQB:TGIFF), a Nevada-focused cannabis consumer packaged goods company, is pleased to announce its first quarter financial results ("Q1 2023") For the three months ended October 31, 2022 and 2021 ("Fiscal 2023"). All amounts expressed are in Canadian dollars. The Company owns 91% of Alternative... Read more


REDUVO Marketing Approval on the Right Path

Last Trade: 0.02 0.0021 10.00

Second Clarifax received from Health Canada. MONTREAL, Dec. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO™ New Drug Submission (NDS). The last update was provided on November 18, 2022. On December 21, 2022, the Company... Read more


MediPharm Labs to Acquire VIVO Cannabis

Last Trade: 0.06 0.0001 0.16

Two global leaders in the medical wellness cannabis industry expected to combine complementary strengths of diversified revenue in multiple markets and channels to create a pro-forma Combined Company with over $50M in annualized revenue, based on Q3 2022.(1)(2)(3)(4) Pro-forma Combined Company is expected to have positive EBITDA(5) synergies of between $7M to $9M on an annualized basis within 12 months closing... Read more


Cansortium Restructures Short-Term Contingent Liability

Last Trade: 0.12 0.001 0.83

MIAMI, Dec. 22, 2022 /CNW/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent™ brand, announces that, pursuant to a third amendment dated December 21, 2022 (the "Third Amendment") to an existing agreement (as amended, the "Smith Transaction Agreement") among the Company and certain of its affiliates and William Smith, a... Read more


Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE

Last Trade: 0.03 0.0005 1.79

Phase 2 clinical trial planned to start in H1 2023 San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration ("FDA") has given the okay to proceed for the Investigational New Drug ("IND")... Read more


Tilray: RIFF Cannabis Brand Launches New Series of Limited-Edition Strains in ‘Joint Effort’ With Craft Growers

Last Trade: 3.21 0.14 4.56

TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the launch of a new limited edition, premium craft flower series by lifestyle brand, RIFF. The brand’s new series is designed to introduce two new collections of craft flower featuring a rotation of limited... Read more


Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

Last Trade: 0.03 0.0005 1.79

San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of SBI-100 Ophthalmic Emulsion ("OE") in the first cohort of healthy participants in the single ascending dose ("SAD") part of its Phase 1 study... Read more


Goodbody Health Announces Cash Injection for Growth Through Divestment of Polish CBD Operations

Last Trade: 0.04 0.0049 15.65

ST PETER PORT, GUERNSEY / ACCESSWIRE / December 16, 2022 / Goodbody Health Limited (AQSE:GDBY)(OTCQB:GDBYF) ("Goodbody" or the "Company"), today announces that that it has agreed to sell the Polish CBD related elements of its operations to Voyager Life PLC ("Voyager") in return for a consideration of £1.5m, comprising £0.5m cash and £1.0m convertible loan notes ("CLNs"). The divestment comprises the share sale of... Read more


HEXO Reports Q1’23 Financial Results

Last Trade: 1.59 -0.04 -2.45

Strategic realignment demonstrates significant results across the business, including quarter over quarter improvements to Adjusted EBITDA and increased gross margin before adjustments HEXO has signed new cultivation agreements and purged unprofitable sales Redecan brand achieved record sales, prompting 300% increase in production GATINEAU, Quebec, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO;... Read more


Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

Last Trade: 0.02 -0.0009 -4.84

LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic. Recently, Gb Sciences received positive preclinical results supporting the efficacy... Read more


The Addition of Three Mental Health Clinics to Irwin Naturals' Florida Footprint Solidifies the Companies Impact as One of the Fastest-Growing Chains of Mental...

Last Trade: 3.08 -0.42 -12.00

LOS ANGELES, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a Florida Mind Health Center. The Company entered into an acquisition agreement (the “Agreement”) dated October 30, 2022 with Clare Clinic, Inc., d/b/a Florida Mind Health Center, which serves clients out of... Read more


SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy

Last Trade: 0.89 -0.03 -3.03

The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced positive results from its study of SCI-210 on Status Epilepticus ("SE"),... Read more


Tilray Brands: Good Supply Cannabis Brand Launches ‘Peppermint Phatty’

Last Trade: 3.21 0.14 4.56

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today the launch of Peppermint Phatty 510 vape, the newest addition to the Good Supply vape lineup. Just in time for the holidays, Peppermint Phatty is packed with peppermint and vanilla aromas and topped off with a... Read more


PharmaCielo Announces First Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Morocco

Last Trade: 0.19 -0.0057 -2.84

Represents PharmaCielo's first shipment to Africa. Morocco is pioneering the commercialization of cannabinoid products on the African continent and will be a growing market. The Company also announced that it has agreed to issue shares in settlement of certain interest payments and debt. TORONTO, Canada and RIONEGRO, Colombia, Dec. 5, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the... Read more


Trulieve Cannabis Opening Medical Marijuana Dispensary in Hobe Sound, Florida

Last Trade: 6.48 0.24 3.85

New dispensary expands patient access to medical cannabis; grand opening specials available TALLAHASSEE, Fla., Dec. 2, 2022 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary in Hobe Sound, Florida. Located at 10835 SE Federal Hwy., the doors will open... Read more


Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

Last Trade: 0.22

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's... Read more


Khiron Life Sciences Reports Third Quarter 2022 Financial Results

Last Trade: 0.09 0.0077 9.44

In Europe, revenues increased by 141% year-over-year, driven by revenues in the United Kingdom, where the Corporation is now increasing its existing product portfolio, and the specialized cannabis clinic Zerenia™ Clinics UK celebrates its first anniversary. Overall revenues for Q3 2022 decreased 24% driven primarily by a reduction of medical cannabis sales in Colombia, due to an interruption in insurance-covered... Read more


Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

Last Trade: 0.22

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth... Read more


Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

Last Trade: 0.66 0.03 4.48

Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with a completely methylated FMR1 gene expected in second half 2023 DEVON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) --... Read more


Incannex Healthcare Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

Last Trade: 3.41 -0.03 -0.84

MELBOURNE, Australia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific (‘Eurofins’) to... Read more


Aleafia Health Successfully Completes TSX Review and Announces Entry into Fifth Province

Last Trade: 0.05

Successful completion of TSX listing review Expansion of adult-use portfolio into key fifth province 5 provinces now selling Aleafia’s adult-use products TORONTO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Further to its previous announcements, Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that it has completed the TSX delisting review and confirms that the... Read more


Medical Marijuana Reports $4.9 Million in Net Revenue in 2022 Third Quarter Financial and Operational Results

Last Trade: 0.008

SAN DIEGO, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending September 30, 2022, and provided an overview of recent... Read more


PreveCeutical Medical Files Application for D-amino Acid Peptides

Last Trade: 0.02 0.0021 9.25

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a PCT (Patent Cooperation Treaty) application number PCT/IB2022/06117 on November 18, 2022, entitled "Peptides and Uses Thereof", with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. This patent... Read more


Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

Last Trade: 2.94 0.10 3.52

PCG Digital -- Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world's biggest public health crises. Lexaria Bioscience The global dementia drug market is projected to reach $32.3 billion by 2030 diabetes and the diabetes drug market is expected to reach $82.92 billion by 2027. Lexaria recently... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS